Invex Therapeutics (ASX:IXC) Total Assets: A$4.72 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IXC Invex Therapeutics Ltd ASX:IXC
32 GF Score
Price A$0.12
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Total Assets?

Invex Therapeutics ASX:IXC 32 Total Assets is A$4.72 Mil as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Invex Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was A$4.72 Mil.

During the past 12 months, Invex Therapeutics's average Total Assets Growth Rate was -2.10% per year. During the past 3 years, the average Total Assets Growth Rate was -14.00% per year. During the past 5 years, the average Total Assets Growth Rate was 12.80% per year.

During the past 6 years, Invex Therapeutics's highest 3-Year average Total Assets Growth Rate was 65.40%. The lowest was -14.00%. And the median was 41.90%.

Total Assets is connected with ROA %. Invex Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 was -28.10%. Total Assets is also linked to Revenue through Asset Turnover. Invex Therapeutics's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Invex Therapeutics  (ASX:IXC) Total Assets Explanation

Total Assets is connected with ROA %.

Invex Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-1.432/( (5.468+4.723)/ 2 )
=-1.432/5.0955
=-28.10 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Invex Therapeutics's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (5.468+4.723)/ 2 )
=0/5.0955
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Invex Therapeutics Total Assets Related Terms

Invex Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Total Assets Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial 32.74 29.49 22.80 6.12 5.47

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.28 6.12 5.86 5.47 4.72
ASX:IXC
32GF Score
Invex Therapeutics Ltd ASX:IXC
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Invex Therapeutics's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=5.247+0.221
=5.47

Invex Therapeutics's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=4.547+0.176
=4.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of A$4.72 Mil mean?
Invex Therapeutics (ASX:IXC) has a Total Assets of A$4.72 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Total Assets too high?
Invex Therapeutics' current Total Assets is A$4.72 Mil. Overall, Invex Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Total Assets compare to VRTX and REGN?
Invex Therapeutics' Total Assets of A$4.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Total Assets is A$4.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Total Assets of A$4.72 Mil. The current Total Assets is A$4.72 Mil. Invex Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Total Assets is A$4.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
32GF Score

Get the complete analysis for ASX:IXC

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price